As states begin to loosen restrictions and we try and put COVID-19 in the rear view mirror, in the words of Bill Gates, "it's going to be a while before we can get back to normal" and companies are going to have to find creative ways to stay connected and engaged while moving forward and getting work done.
The following is a small sampling of Regenerative Medicine segment updates from the past week that were compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present news, analysis, studies, trial results, patents and financial data that are most relevant to our subscribers.
For 2020, the TOBI Conference was held virtually due to COVID-19; still, attendance was fairly high. During one of the Virtual Lounge Q&A discussions, it appears that there is an emerging trend w/ some practitioners doing PRP inj then HA inj, not the other way around for knee.
BOTHE informed that in EU several clinical sites for JTA-004 Phase III trial have resumed recruitment as COVID-19 lockdown measures are lifted; 34 pts have been treated since the initiation of the trial mid-May 2020. Reporting of the topline results is currently planned for H221.
This study presents a detachable hybrid microneedle depot (d‐HMND) for cell delivery The system deploys an array of "microneedles" w/ MSCs embedded in a gel-like matl, which prolongs cell viability & functionality, penetrating into a target tissue w/ high spatial precision. ADFM
US Patent Application “PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF” was published, relating to compositions for PRP depleted in neutrophils to treat damaged connective tissue &/or slow/stop cardiac apoptosis after a heart attack, along w/ reperfusion therapy. 20200179455